anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. Technical Result Increase in treatment efficiency, prevention of complications and side effects. 2. Essence A composition for treatment of infectious diseases comprises a phytochemical substance obtained from Echinacea purpurea and folic acid. Said composition is applied for treatment of influenza, encephalitis, meningitis, cellulitis, bacterial encephalitis, bacterial meningitis and diseases caused by the viruses of herpes simplex 1, herpes simplex 2, Zoster, human immunedeficiency, Epstein-Barr, cytomegalovirus, papillomavirus, adenovirus, arbovirus, arenovirus, pykornovirus, coronavirus, sinstialvirus, staphylococcus, streptococcus and anaerobic bacillus. 3. Field of Application Medicine.
The present invention relates to a novel five-kind compound medicine prepared from pure traditional Chinese medicines for treating premenstrual syndrome and a preparation method thereof. The compound medicine of the present invention is prepared from the following raw materials and/or pharmaceutic adjuvants of white peony root, tree peony bark and nutgrass galingale rhizome. The preparation method comprises the following steps that the white peony root is extracted by soaking with ethanol, adsorbed with a resin column, and eluted to obtain an extract of the white peony root. The tree peony bark is distillated with steam, a receiving liquid is refrigerated, filtered and crystallized to obtain an extract of the tree peony bark. The nutgrass galingale rhizome is heated for extracting volatile oil, and beta-cyclodextrin is added to obtain an inclusion compound of the volatile oil of the nutgrass galingale rhizome and the beta-cyclodextrin. The novel five-kind compound medicine prepared from pure traditional Chinese medicines for treating premenstrual syndrome of the present invention has the advantages of obvious curative effect, few medicinal ingredients, high purity and little side effect. The prepration method of the medicine of the present invention has the advantages of high extraction rate, high purity and simple operation, and is suitable for industrial production.
The e-CPD device will be given to the participant group according to the criteria. Each participant is given access rights for 1 week to try all the features in e-CPD.
The recommended initial dose of Irbesartan is 150 mg once daily. Patients requiring further reduction in blood pressure should be titrated to 300 mg once daily.

A low dose of a diuretic may be added, if blood pressure is not controlled by Irbesartan alone. Hydrochlorothiazide has been shown to have an additive effect (see CLINICAL PHARMACOLOGY: Clinical Studies). Patients not adequately treated by the maximum dose of 300 mg once daily are unlikely to derive additional benefit from a higher dose or twice-daily dosing.

No dosage adjustment is necessary in elderly patients, or in patients with hepatic impairment or mild to severe renal impairment.
INTRODUCTION: Bariatric surgery aims for optimal patient outcomes, often evaluated through the percentage total weight loss (%TWL). Quality registries employ funnel plots for outcome comparisons between hospitals. However, funnel plots are traditionally used for dichotomous outcomes, requiring %TWL to be dichotomized, potentially limiting feedback quality. This study evaluates whether a funnel plot around the median %TWL has better discriminatory performance than binary funnel plots for achieving at least 20% and 25% TWL.
METHODS: All hospitals performing bariatric surgery were included from the Dutch Audit for Treatment of Obesity. A funnel plot around the median was constructed using 5-year %TWL data. Hospitals positioned above the 95% control limit were colored green and those below red. The same hospitals were plotted in the binary funnel plots for 20% and 25% TWL and colored according to their performance in the funnel plot around the median. We explored the hospital's procedural mix in relation to %TWL performance as possible explanatory factors.
RESULTS: The median-based funnel plot identified four underperforming and four outperforming hospitals, while only one underperforming and no outperforming hospitals were found with the binary funnel plot for 20% TWL. The 25% TWL binary funnel plot identified two underperforming and three outperforming hospitals. The proportion of sleeve gastrectomies performed per hospital may explain part of these results as it was negatively associated with median %TWL (β =  - 0.09, 95% confidence interval [- 0.13 to - 0.04]).
CONCLUSION: The funnel plot around the median discriminated better between hospitals with significantly worse and better performance than funnel plots for dichotomized %TWL outcomes.
An image acquisition and analysis system is disclosed. The system enables high throughput, objective analysis of microbial samples over days or weeks. The system may accommodate upwards of twelve 96- or 384-well plates simultaneously (liquid or solid media). The system may acquire and analyze a large number of samples in a short period of time. For example, over 384 samples per minute or 18,432 samples per hour. The system hardware may include a multi-spectral imager (fluorescence and bright field detection), electro-mechanical assemblies, and an optional high-resolution stage. The system may automate image acquisition, image data processing, simplify data storage, and enable automated analysis tools to significantly reduce the manual labor and time associated with such tasks. The system may allow for quick processing and analysis of data into clear phenotypic classes. The analysis capabilities may include colony growth, colorimetry, and structural morphology assays, and automated phenotype classification capabilities.
The antihypertensive effects of Aliskiren have been demonstrated in 6 randomized, double-blind, placebo-controlled 8- week clinical trials in patients with mild-to-moderate hypertension. The placebo response and placebo-subtracted changes from baseline in seated trough cuff blood pressure are shown in Table 2. 

*p value less than 0.05 versus placebo by ANCOVA with Dunnett's procedure for multiple comparisons  
†p value less than 0.05 versus placebo by ANCOVA for the pairwise comparison. 

The studies included approximately 2,730 patients given doses of 75 mg (0.5 times the lowest recommended dosage) to 600 mg (twice the highest recommended dosage) of aliskiren and 1,231 patients given placebo. The recommended dosage of Aliskiren is either 150 or 300 mg once daily [see Dosage and Administration (2.1)]. As shown in Table 1, there is some increase in response with administered dose in all studies, with reasonable effects seen at 150mg to 300mg, and no clear further increases at 600 mg. A substantial proportion (85% to 90%) of the blood pressure-lowering effect was observed within 2 weeks of treatment. Studies with ambulatory blood pressure monitoring showed reasonable control throughout the interdosing interval; the ratios of mean daytime to mean nighttime ambulatory BP range from 0.6 to 0.9. 

Patients in the placebo-controlled trials continued open-label aliskiren for up to 1 year. A persistent blood pressure-lowering effect was demonstrated by a randomized withdrawal study (patients randomized to continue drug or placebo), which showed a statistically significant difference between patients kept on aliskiren and those randomized to placebo. With cessation of treatment, blood pressure gradually returned toward baseline levels over a period of several weeks.

Aliskiren lowered blood pressure in all demographic subgroups, although black patients tended to have smaller reduction than Caucasians and Asians, as has been seen with ACEIs and ARBs.

There are no studies of Aliskiren or members of the direct renin inhibitors demonstrating reductions in cardiovascular risk in patients with hypertension.
The intervention arm will involve (i) the delivery of a blended learning education program and (ii) weekly phone calls to participants. The lectures will be delivered to 10 teams, comprised of about 15 participants in each team and lead by a volunteer team leader using the ORCD's laptop, overhead projector and the sound system in local clubs, school premises or participants' houses. The ORCD investigator including the physician and an information technology person will facilitate the education programs. The interpretations or additional explanations will be made by the physician following WHO guidelines and recommendations\[36\]. The investigator will maintain a folder for each team and will communicate at least with the team leaders by phone calls once every week to remind them to adhere to lifestyle modification intervention program. The weekly monitoring program will continue until the study ends.
A flexible implantable contraceptive disc device is disclosed which can be inserted inside the female body, such as inside the uterus, is disclosed. The circular device can be bent and inserted into a laparoscopy tube which allows it to be delivered to the appropriate location inside a female subject. The disc has three layers, a central core silicon reservoir containing the active ingredient, such as a contraceptive progesterone, which is sandwiched and encased by an upper and lower porous silicon casings. The casings are porous to the contraceptive, allowing controlled release over a prolonged period of time. The lower casing has a series of micro-hooks around the discs circumference, allowing the disc device to be attached to a desired tissue by rotating the disc such that the hooks engage with the tissue. Such a device is easier to insert, and to remove, than the rod-like rigid plastic T-shape IUDs which are considerably larger, also more expensive to manufacture.
Compositions comprising a mixture of peptides that bind to molecules involved in Bcr-Abl oncoprotein function are disclosed. In addition, expression of functional BCR protein (p160 BCR) or amino terminal fragments thereof (159, 221 and 413 amino terminal residues) by way of retrovirus vectors will oppose the biological function of Bcr-Abl (p160 BCR) or inactivate Bcr-Abl tyrosine kinase function or its signal transduction function. Bcr and Abl peptides, either tyrosine phosphorylated or unphosphorylated, that bind to a region near the amino terminus of Bcr to prevent formation of tetramer Bcr-Abl molecules, that bind to the SH2 domain of Grb2, to sites on tyrosine phosphorylated Shc protein, to sites of Crkl, and to an SH2 domain of Ras Gap comprise particular peptide preparations of the invention. The peptides and polypeptides inhibit Bcr-Abl oncoprotein activation, or block the oncogenic signal generated by the Bcr-Abl oncoprotein and, thereby, inhibit growth and induce cell death of leukemia cells expressing the oncoprotein. Methods for processing bone marrow using the peptide and polypeptide compositions of the invention are also provided. Stem cells present in bone marrow may thus be enriched for Philadelphia chromosome-negative cells prior to transplantation, particularly as part of autologous bone marrow transplant therapy of leukemia, including CML, ALL and AML.
Each subject will have a PET scan at \[18F\] FDG.The raw imaging data obtained from these controls will be post-processed using the Statistical Parametric Mapping software. Schematically, the data of each control will be normalized in the same anatomical space, then smoothed and averaged between the different controls. This will make it possible to constitute the normative database.
CHF is a common and devastating health problem estimated to affect upwards of 26 million individuals worldwide. Following an initial hospitalization for heart failure, approximately 25% of patients are readmitted within the first 30 days of discharge. Repeat heart failure hospitalizations are a major burden on both patients and healthcare systems. To date, there is an absence of non-invasive solutions proven to reduce the risk of re-hospitalization for CHF.

The key feature of the physical examination for assessing the volume status of CHF patients is the JVP, which manifests as a biphasic pulsation along the neck. The height of the JVP relative to the sternal angle is a reflection of right atrial pressure, which increases in response to higher pressures transmitted from the left side of the heart. Pathologic elevation of left sided heart pressures can result in fluid congestion in the lungs, which can cause patients to develop shortness of breath and reduced blood oxygen levels. Although a crucial marker of volume status, accurate identification of the JVP can be challenging for physicians due to its pulsations often being subtle.

The JVPHome is a novel medical device designed to facilitate visualization of JVP height relative to the sternal angle through the use of machine vision. The current study aims to evaluate the JVPHome in a clinic setting when the device is applied to CHF patients by clinicians. Following its application, the JVPHome will be allowed to record a video of the JVP and images will subsequently be transmitted to a secure cloud and undergo analysis with machine vision software. JVP height of study participants will be concurrently assessed through the use of ultrasound (gold standard). Clinicians that are blinded to ultrasound determined JVP height values will assess JVP height values remotely based on the machine enhanced images generated by the JVPHome. Analyses will then assess the accuracy of the JVPHome relative to ultrasound and expert clinical assessment.
Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
Sarcopenia is characterised by the loss of skeletal muscle mass and function, which leads to a high risk of increased morbidity and mortality. Maternal malnutrition has been linked to impaired development of skeletal muscle of the offspring; however, there are limited studies that report the long-term effect of a maternal low-protein diet during lactation on the ageing of skeletal muscles. This study aimed to examine how a maternal low-protein diet (LPD) during lactation affects skeletal muscle ageing in the offspring. Pups born from control mothers were lactated by mothers fed with an LPD. Post-weaning, mice were either maintained on an LPD or switched to a control, normal-protein diet (NPD). In males, an LPD mainly affected the size of the myofibres without a major effect on fibre number and led to reduced grip strength in ageing mice (24 months). Female mice from mothers on an LPD had a lower body and muscle weight at weaning but caught up with control mice at 3 months. During ageing, the muscle weight, myofibre number and survival rate of female pups were significantly affected. These findings highlight the effect of an LPD during lactation on skeletal muscle ageing, the lifespan of offspring and the importance of sexual dimorphism in response to dietary challenges.
<P>PROBLEM TO BE SOLVED: To provide transdermally absorbable low molecular peptides which have mol. wts. of ≤3,000 and are contained in materials obtained by separating and recovering substances having cell growth-promoting functions from low molecular compounds originated from fibroins of safe natural products, as skin care raw materials aiming the maintenance and recovery of healthy skins.  <P>SOLUTION: The mol. wts. of silk fibroins are lowered to divide into a cell growth-promoting function component and a cell growth-inhibiting component without dissolving silk. A method therefor comprises immersing crystalline silk powder in water, and low molecular compounds are extracted from the supernatant. The obtained extract has a cell growth-promoting function, and contains the transdermally absorbable low molecular peptides having mol. wts. of 400 to 3,000 in an amount of 50 to 99%.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The process of producing a beverage for enhancing athletic performance comprises selecting an amount of beet product as a solute. The process of producing a beverage includes infusing water with a molecular hydrogen in a desired amount to produce hydrogen infused water as a solvent. The process further includes mixing the solute into the solvent to produce the beverage for providing controlled reduction of nitrates. The proposed invention further relates to a beverage composition providing controlled reduction of nitrates in a human body. The composition of the beverage comprises one or more beet products, and a hydrogen infused water. The proposed beverage is capable of stabilizing the nitrates content, and controlling reduction of nitrates to nitric oxide in the blood plasma, which is effective for enhancing one's athletic performance.
Subjects who Drug naïve we will give Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).Subject who are on metformin at time of randomization we will add Glipizide 5 mg( to be increased to 10 mg at Visit 5), Subject who are on Glipizide at time of randomization will have Metformin- XR, 1000 mg/day added. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).
At Visit 1, JUVÉDERM filler injections (Juvéderm VOLBELLA with lidocaine, Juvéderm VOLIFT with lidocaine, and/or Juvéderm VOLUMA with lidocaine) will be administered. At Visit 4, JUVÉDERM VOLBELLA with lidocaine, may be administered in the infraorbital hollow (IOH)/tear trough (TT) area. At Visit 6, participants will receive BOTOX/VISTABEL. Touch-ups may be performed as required based on investigator's assessment.
Empirically supported behavioral treatments cannot be effectively disseminated without understanding key quality components. Mechanism-informed quality measures have extraordinary potential to enhance pragmatism by eliminating unnecessary elements and targeting multiple problems and populations, and to enhance predictive value by detecting mechanism engagement early in treatment. Community Mental Health Agencies (CMHAs), however, are often ill-equipped to use such measures of treatment quality due to burden and limited resources. Exposure therapy for anxiety is an ideal prototype for testing a practical, mechanism-informed quality measure in CMHAs given its potential for public health impact and clear theory of mechanism. The Exposure Guide (EG), a brief quality tool measuring therapist behaviors and mechanism, was developed based on microanalytic coded data showing a strong link between therapist behavior and patient outcome across three RCTs of exposure therapy in youth. Initial psychometrics for the EG using these RCT data are promising showing reliability, construct validity, and predictive validity, and pilot data suggests it may be acceptable and feasible in a community setting. Building upon these findings, we propose to test this novel measure of exposure quality, EG, in a community setting including its reliability and validity, its pragmatism, and which community end-users can become reliable and valid reporters. Therapists at a large local CMHA (N = 40) treating anxious youth and young adults ages 5-25 (N = 300) will participate in this study. The EG will be completed by 1) agency supervisors monthly, 2) therapists per session, 3) patient/families per session, and 4) study raters per session. Results from this study will establish an innovative model for measuring therapeutic elements that trigger mechanism of change in real-world therapy as well as inform future use of EG as a training tool to improve exposure quality in community settings.
Teratogenic Effects. Pregnancy Category C

Codeine \- A study in rats and rabbits reported no teratogenic effect of codeine administered during the period of organogenesis in doses ranging from 5 to 120 mg/kg. In the rat, doses at the 120 mg/kg level, in the toxic range for the adult animal, were associated with an increase in embryo resorption at the time of implantation. In another study a single 100 mg/kg subcutaneous dose of codeine administered to pregnant mice reportedly resulted in delayed ossification in the offspring. 

There are no adequate and well-controlled studies in pregnant women. Acetaminophen and codeine phosphate tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
PURPOSE:To obtain a quick-drying agent for nail enamels containing specified amount of a specific low-viscosity silicon oil dissolving in a solvent therein, capable of improving drying rate of the nail enamels by applying the agent to the film surfaces coated with the nail enamels. CONSTITUTION:A quick-drying agent for nail enamels obtained by dissolving a low-viscosity silicon oil (e.g. straight-chain dimethylpolysiloxane, cyclic dimethylpolysiloxane, cyclic tetramethylpolysiloxane or cyclic pentamethylpolysiloxane having 0.5-20cSt viscosity) having <=20cSt viscosity in a solvent (especially preferably a saturated hydrocarbon-based solvent having a branched chain) and incorporating 1-30wt.% silicon oil therein. When the aforementioned agent is used after coating the nail enamels, remarkable effects are provided as follows. Quick-drying effects are remarkably improved. Since the content of the low-viscosity silicone oil is 1-30wt.%, no citron-like skin, etc., will occur on the surface even in recoating after removing the nail enamels with an enamel remover without extremely increasing residual properties after the coating.
Symptoms of depression and anxiety are extremely prevalent in the population. Unfortunately, patients often face barriers to accessing mental health care, particularly psychotherapeutic interventions, including long wait-times and demanding therapeutic protocols. For instance, standardized MBIs such as mindfulness-based cognitive therapy (MBCT) and mindfulness-based stress reduction (MBSR) are typically eight weeks in length. MBSR and MBCT, traditional MBTs, can demand over 30 hours of clinical time, and 50-60 hours of homework, all of which can be barriers to care. Furthermore, many clients are unable to access in-person interventions. At present the Sunnybrook Mindfulness Clinic is not conducting any virtual services due to the unknown benefit of virtual mindfulness interventions, creating significant barriers to clinical care for patients. The goal of this project is to compare the effectiveness of virtually delivered, abbreviated MBI (\<10 hours of clinical time and \<10 hours of homework) to a wait-list control condition in terms of reducing symptoms of depression/anxiety/stress and improving wellbeing. If effective, this abbreviated MBI conducted virtually could enable clients to pursue virtual services during the current COVID-19 pandemic.

MBTs use a non-stigmatizing approach, combining secularized eastern meditative practices with western psychological advances to improve stress-management and self-care. Participants learn to generate less distress, engage more positively and fully in their lives and experiences, and respond more adaptively to challenges instead of reacting in automatic and unhelpful ways. Participants in MBI often describe the intervention as transformative. The abbreviated MBI protocol has been piloted in an uncontrolled study and indicated significant benefit for patients in terms of symptom improvement. However, this will be the first time that the investigators pilot a virtual adaptation to the mindfulness group.